Logo

Pfizer and BioNTech Report Results of COVID-19 Vaccine Booster in P-III Trial for the Treatment of COVID-19

Share this
Pfizer and BioNTech Report Results of COVID-19 Vaccine Booster in P-III Trial for the Treatment of COVID-19

Pfizer and BioNTech Report Results of COVID-19 Vaccine Booster in P-III Trial for the Treatment of COVID-19

Shots:

  • The P-III trial evaluates a booster dose of COVID-19 vaccine (30µg) in a ratio (1:1) in 10000+ individuals aged ≥16yrs. with COVID-19 who previously received the primary two-dose series of vaccine
  • The results showed vaccine efficacy of 95.6% compared to a non-boosted group- median time b/w second & booster dose was ~11mos.- symptomatic COVID-19 occurrence was measured from 7 days after booster with a median follow-up of 2.5mos.- AEs profile was consistent with other clinical safety data for vaccine & no safety concerns were observed
  • The companies also plan to share the data with the US FDA- EMA & other regulatory agencies globally to support license in the US & other countries shortly

Click here ­to­ read full press release/ article | Ref: Pfizer | Image: Hindustan Times


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family